Hangzhou Hekang Pharmaceutical Co., Ltd.

Primary objective: To compare the absorption rate and extent of dotenorazole tablets (2 mg) supplied by Hangzhou Hekang Pharmaceutical Co., Ltd. with that of dotenorazole tablets (2 mg, brand name: URECE®) certified by Fuji Pharmaceutical Co., Ltd. in a healthy adult population under fasting and postprandial administration conditions, and to evaluate their bioequivalence. Secondary objective: To evaluate the safety of dotenorazole tablets (2 mg) supplied by Hangzhou Hekang Pharmaceutical Co., Ltd. with that of dotenorazole tablets (2 mg, brand name: URECE®) certified by Fuji Pharmaceutical Co., Ltd. in a healthy adult population under fasting and postprandial administration conditions.

To investigate the pharmacokinetic characteristics of a single oral dose of phenbarate tablets (test preparation T, strength: 12.5 mg) provided by Hangzhou Hekang Pharmaceutical Co., Ltd. and a single oral dose of phenbarate tablets (reference preparation R, trade name: ONTOZRY®, strength: 12.5 mg) certified by Angelini Pharma S.p.A. in healthy subjects after a meal, and to evaluate the bioequivalence and safety of the two preparations, so as to provide a basis for the registration application of the test preparation.

Primary objective: To evaluate the safety and tolerability of single/multiple administrations of ramosetron hydrochloride sustained-release patch in healthy Chinese adult subjects. Secondary objective: To evaluate the pharmacokinetic characteristics and adhesion of ramosetron hydrochloride sustained-release patch in healthy Chinese adult subjects after single/multiple administrations.